Product Spotlight The 2018 OPPS final rule is one of the most controversial in recent years, with CMS drastically cutting payments for drugs purchased under the 340B drug discount program and adding payment modifiers to report. During this webinar, Jugna Shah, MPH, and Valerie A. Rinkle, MPA, will analyze the rule and deliver a comprehensive program on preparing for the major changes coming in 2018. |